ABBV(ABBV)
ABBV
Product Revenue Segments
Latest: 2025 (2025-12-31) · Total: $58.17B
| Segment | Revenue | Share |
|---|---|---|
SKYRIZI | $17.56B | 30.2% |
RINVOQ | $8.30B | 14.3% |
H U M I R A | $4.54B | 7.8% |
Botox Therapeutic | $3.77B | 6.5% |
Vraylar | $3.62B | 6.2% |
Imbruvica | $2.87B | 4.9% |
VENCLEXTA | $2.79B | 4.8% |
Other Products | $2.63B | 4.5% |
Botox Cosmetic | $2.60B | 4.5% |
MAVYRET | $1.32B | 2.3% |
Ubrelvy | $1.27B | 2.2% |
Other Aesthetics | $1.26B | 2.2% |
Qulipta | $1.04B | 1.8% |
Other Eye Care | $1.01B | 1.7% |
Juvederm Collection | $993.0M | 1.7% |
Linzess/Constella | $907.0M | 1.6% |
Ozurdex | $493.0M | 0.8% |
Lumigan/Ganfort | $410.0M | 0.7% |
Duodopa | $381.0M | 0.7% |
Other Neuroscience | $207.0M | 0.4% |
Alphagan/Combigan | $197.0M | 0.3% |
Other | $0 | 0.0% |
Geographic Revenue Segments
Latest: 2025 (2025-12-31) · Total: $48.97B
| Segment | Revenue | Share |
|---|---|---|
UNITED STATES | $46.60B | 95.2% |
Non-US | $2.36B | 4.8% |
Source: SEC filings via FMP · Last updated May 25, 2026